Shareholding disclosure

Remo und Manuela Stoffel

Declared position

12.077%

Threshold

Crossed upwards

Timeline

Published

21.12.2017

Transaction

13.12.2017

Transfer date

15.12.2017

Voting rights breakdown

Voting rights acquired12.077%

Voting rights sold1.46%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAHCK00054

Beneficial owner

Remo und Manuela Stoffel

Declared address

Remo und Manuela Stoffel, 7000 Chur

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Remo und Manuela Stoffel

Vifor Pharma AG21.12.2017TAHCK00054

Disclosure summary

Remo und Manuela Stoffel disclosed a holding in Vifor Pharma AG on the acquisition side, published by SIX Exchange Regulation on 21.12.2017, at 12.077% of voting rights. Notice category: Single shareholder.

Disclosed position

12.077%

Voting rights acquired

Voting rights acquired12.077%

Voting rights sold1.46%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Remo und Manuela Stoffel disclosed a holding in Vifor Pharma AG, published on 21.12.2017.

Publication date21.12.2017

Transaction date13.12.2017

Transfer date15.12.2017

Issuing companyVifor Pharma AG

Beneficial ownerRemo und Manuela Stoffel

Declared addressRemo und Manuela Stoffel, 7000 Chur

CategorySingle shareholder

Voting rights acquired12.077%

Voting rights sold1.46%

Below threshold0%

ExchangeXSWX

Notification IDTAHCK00054

Source: SIX Exchange Regulation · Publication date: 21.12.2017

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open